| Date | Title | Description |
| 11.10.2024 | Europe takes the lead: New ranking reveals surprising shift in the global venture capital landscape | The venture capital landscape, a critical driver of innovation and startup growth, has long been dominated by U.S.-based firms. These firms traditionally lead the way in funding emerging technologies and disruptive businesses globally. Howe... |
| 08.04.2024 | D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline | SHANGHAI, April 8, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, ... |
| 23.02.2024 | Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline | - |
| 11.02.2024 | Medicxi merges 6 dermatology biotechs into one, adds $100M funding for launch | What do you get when you merge six dermatology disease-focused biotechs into one? Medicxi plans to find out.
The London-headquartered venture capital firm is combining six of its portfolio companies together, adding in a $100 million shot o... |
| 02.10.2023 | 'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023 | While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused venture capital firms don’t seem to have had problems bringing in money.
In fact, both Forbion and BioGeneration Ventures announced their largest ... |
| 28.07.2023 | Medicxi IV to boost the European Life sciences sector with $400m | |
| 27.07.2023 | Medicxi Launches $400M Fund IV | Medicxi, a London, UK- Geneva, Switzerland- and Jersey-based life sciences investment firm, announced its $400m Fund IV.
Medicxi IV will continue to support drug hunters with clear product visions to deliver transformative therapies for pat... |
| 27.07.2023 | Medicxi Announces $400m Medicxi IV | - |
| 19.01.2023 | The Week in Agrifoodtech: Sollum Technologies nabs $30m; phantom carbon credits & food delivery shutdowns | Sollum Technologies raised the largest funding round this week, for its programmable LED lighting for greenhouses. Multus Biotechnology also secured funding, while The Guardian and others unveiled an investigation into a nonprofit for what ... |
| 17.02.2021 | Three Cambridge spin-outs join Centessa Pharmaceuticals, launched with a $250m Series A round | Three Cambridge spin-outs join Centessa Pharmaceuticals, launched with a $250m Series A round
17-02-2021
ApcinteX, Morphogen-IX, Z Factor join seven other privately held biotech companies in a new type of pharmaceutical R&D model.
Cente... |
| 19.11.2020 | SynOx Therapeutics raises €37M in Series A Financing | DUBLIN, Nov. 19, 2020 /PRNewswire/ — SynOx Therapeutics Ltd (“SynOx”), a clinical stage bio pharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forb... |
| 22.09.2020 | Medicxi announces the closing of its first €200 million Secondary Fund, led by Pantheon with co-lead LGT Capital Partners | - |
| 23.09.2019 | Divide & Conquer Launches With $13M in Series A Financing | Divide & Conquer, a Cambridge, UK-based biotechnology company, emerged from stealth with £10m (approximately $13.1m) in Series A financing.
Medicxi made the investment.
Divide & Conquer initially focuses on glioblastoma, a lethal fo... |
| 19.07.2019 | Medicxi closes a €400M Fund to back biopharma entrepreneurs | |
| 19.07.2019 | Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters | - |
| 02.04.2019 | Aura Biosciences cierra una ronda Serie D de $40M liderada por Medicxi, acuden Ysios, Advent Life, Aris Bioscience, Chiesi, ColumbusVP y Lundbeckfonden | 02/04/2019
Nota de prensa
AURA BIOSCIENCES CIERRA UNA RONDA SERIE D DE $40 MILLONES LIDERADA POR MEDICXI, ACUDEN YSIOS CAPITAL, ADVENT LIFE SCIENCES, ARIS BIOSCIENCE, CHIESI, COLUMBUSVP Y LUNDBECKFONDEN.
Aura Biosciences, a leader in the... |
| 09.07.2018 | Morphogen-IX announces appointment of CEO and SAB members | Morphogen-IX announces appointment of CEO and SAB members
09-07-2018
Morphogen-IX Ltd, a preclinical biotechnology company focused on the development of bone morphogenetic proteins for the treatment of pulmonary arterial hypertension (PAH),... |
| 09.07.2018 | Morphogen-IX announces appointment of CEO and SAB members | Morphogen-IX Ltd, a preclinical biotechnology company focused on the development of bone morphogenetic proteins for the treatment of pulmonary arterial hypertension (PAH), has announced the appointment of Professor Nick Morrell as CEO. Morr... |
| 07.06.2018 | TPG Leads $85M Series C for SutroVax | SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the closing of an upsized $85 million Serie... |
| 20.03.2018 | Medicxi founds biotech creation engine C21Med | Medicxi has created an “ideas factory” to boost its capacity to turn early-stage science into pipelines of drug candidates and startups to develop them. The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson ... |
| 20.03.2018 | Medicxi founds biotech creation engine C21Med | Medicxi has created an “ideas factory” to boost its capacity to turn early-stage science into pipelines of drug candidates and startups to develop them. The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson ... |
| 20.01.2018 | Startup fundraising and exits look bullish for bio and health | Joanna Glasner Contributor
Joanna Glasner is a reporter for Crunchbase.
More posts by this contributor
What does it take to be a startup that raises huge sums quickly?
Not a minimalist? Startups will gladly store, manage and deliver your it... |
| 08.01.2018 | This 1-Year-Old Pharma Startup Landed a $1B Buyout | John Hood formed Impact Biomedicines to carry on an abandoned clinical research. John Moore/Getty Images
Impact Biomedicines, a San Diego, Calif.-based startup that recently closed its first round of fundraising, is now an overnight unicorn... |
| 15.06.2017 | Medicxi Launches $300M Late-Stage Life Sciences Fund | Medicxi, a London and Geneva-based life sciences venture capital firm, closed its first late-stage fund, at $300m.
Cornerstone strategic investors in MG1 are Novartis, Verily, an Alphabet company, and the European Investment Fund (EIF).
The... |
| 15.06.2017 | Google backs Swiss based life sciences fund | |
| 04.05.2017 | Z Factor announces £7 million Series A funding to bring lung treatment to clinic | Z Factor announces £7 million Series A funding to bring lung treatment to clinic
04-05-2017
Z Factor Limited announced that it has completed a £7 million Series A investment led by existing investor Medicxi. Cambridge Enterprise & Cambr... |
| 04.05.2017 | Z Factor announces £7 million Series A funding to bring lung treatment to clinic | Z Factor Limited announced that it has completed a £7 million Series A investment led by existing investor Medicxi. Cambridge Enterprise & Cambridge Innovation Capital have also joined in the founding round.
Add This Share Buttons
Found... |
| 16.02.2017 | SuperX Completes $11M Series A Funding | SuperX Ltd, a Cambridge, UK-based biopharmaceutical company, completed an $11m Series A funding.
The round was led by Medicxi with participation from Johnson & Johnson Innovation – JJDC, Inc., the corporate venture arm of Johnson & ... |
| 04.09.2016 | The biotech empires of Silicon Valley and Europe | Bérénice Magistretti Contributor
Bérénice Magistretti is a Swiss freelance writer based in San Francisco. She focuses on startups in Saudi Arabia, Switzerland and emerging markets.
More posts by this contributor
Disrupting the world of scie... |
| - | SynOx Therapeutics raises €37M in Series A Financing | Dublin, Ireland, November 19, 2020 –SynOx Therapeutics Ltd (“SynOx”), a clinical stage biopharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbio... |
| - | GSK fires ex-Operation Warp Speed chief Moncef Slaoui over ‘substantiated’ sexual harassment claims | Moncef Slaoui was fired as Galvani Bioelectronics board chairman over “substantiated” allegations of sexual harassment, pharmaceuticals giant GlaxoSmithKline said.
Slaoui was chief scientist of the U.S. government’s Covid vaccine developmen... |
